血液系统肿瘤治疗相关噬血细胞综合征的诊疗进展

刘艺; 郭涛

doi:10.13201/j.issn.1004-2806.2022.01.004

血液系统肿瘤治疗相关噬血细胞综合征的诊疗进展

刘艺¹,
郭涛^1, ,

- 华中科技大学同济医学院附属协和医院血液内科(武汉，430022)
基金项目:
国家自然科学基金面上项目(No：81974008)

详细信息

作者简介:
专家简介：郭涛，华中科技大学同济医学院附属协和医院血液科主任医师、博士生导师。担任中国医师协会血液科医师分会委员，海峡两岸医药卫生交流协会血液病学专业委员会副主任委员，武汉血液学会主任委员，中国研究型医院协会生物治疗学组常务委员。《临床血液学杂志》，《血栓与止血学》，《国际输血及血液学杂志》及《临床急诊杂志》编委。湖北省噬血细胞综合征专家联盟理事长

通讯作者: 郭涛，E-mail：guotao1968@163.com

中图分类号: R55

收稿日期: 2021-11-24

刊出日期: 2022-01-01

Progress in diagnosis and treatment of hemophagocytic syndrome related to the treatment of hematological tumors

LIU Yi¹,
GUO Tao^1, ,

More Information

Corresponding author: GUO Tao, E-mail: guotao1968@163.com

Received Date: 24 November 2021

Publish Date: 01 January 2022

摘要

- 噬血细胞综合征 /
- 血液系统肿瘤 /
- 治疗 /
- 诊断
- hemophagocytic syndromes /
- hematological tumors /
- treatment /
- diagnosis

HTML全文

参考文献(37)

[1]	Daver N, McClain K, Allen CE, et al. A consensus review on malignancy-associated hemophagocytic lymphohistiocytosis in adults[J]. Cancer, 2017, 123(17): 3229-3240. doi: 10.1002/cncr.30826
[2]	Griffin G, Shenoi S, Hughes GC. Hemophagocytic lymphohistiocytosis: An update on pathogenesis, diagnosis, and therapy[J]. Best Pract Res Clin Rheumatol, 2020, 34(4): 101515. doi: 10.1016/j.berh.2020.101515
[3]	Sepulveda FE, de Saint BG. Hemophagocytic syndrome: primary forms and predisposing conditions[J]. Curr Opin Immunol, 2017, 49: 20-26. doi: 10.1016/j.coi.2017.08.004
[4]	La Rosée P, Horne A, Hines M, et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults[J]. Blood, 2019, 133(23): 2465-2477. doi: 10.1182/blood.2018894618
[5]	Lehmberg K, Nichols KE, Henter J, et al. Consensus recommendations for the diagnosis and management of hemophagocytic lymphohistiocytosis associated with malignancies[J]. Haematologica(Roma), 2015, 100(8): 997-1004.
[6]	Bergsten E, Horne A, Arico M, et al. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study[J]. Blood, 2017, 130(25): 2728-2738. doi: 10.1182/blood-2017-06-788349
[7]	Jordan MB, Allen CE, Greenberg J, et al. Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: Recommendations from the North American Consortium for Histiocytosis(NACHO)[J]. Pediatr Blood Cancer, 2019, 66(11): e27929.
[8]	Sandler RD, Tattersall RS, Schoemans H, et al. Diagnosis and Management of Secondary HLH/MAS Following HSCT and CAR-T Cell Therapy in Adults; A Review of the Literature and a Survey of Practice Within EBMT Centres on Behalf of the Autoimmune Diseases Working Party(ADWP)and Transplant Complications Working Party(TCWP)[J]. Front Immunol, 2020, 11: 524. doi: 10.3389/fimmu.2020.00524
[9]	Vick EJ, Patel K, Prouet P, et al. Proliferation through activation: hemophagocytic lymphohistiocytosis in hematologic malignancy[J]. Blood Adv, 2017, 1(12): 779-791. doi: 10.1182/bloodadvances.2017005561
[10]	Takagi S, Masuoka K, Uchida N, et al. High incidence of haemophagocytic syndrome following umbilical cord blood transplantation for adults[J]. Br J Haematol, 2009, 147(4): 543-553. doi: 10.1111/j.1365-2141.2009.07863.x
[11]	Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade[J]. N Engl J Med, 2018, 378(2): 158-168. doi: 10.1056/NEJMra1703481
[12]	Henter JI, Horne A, Arico M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis[J]. Pediatr Blood Cancer, 2007, 48(2): 124-131. doi: 10.1002/pbc.21039
[13]	中国抗癌协会淋巴瘤专业委员会. 淋巴瘤相关噬血细胞综合征诊治中国专家共识[J]. 中华医学杂志, 2018, 98(18): 1389-1393. doi: 10.3760/cma.j.issn.0376-2491.2018.18.004
[14]	Abdelkefi A, Jamil WB, Torjman L, et al. Hemophagocytic syndrome after hematopoietic stem cell transplantation: a prospective observational study[J]. Int J Hematol, 2009, 89(3): 368-373. doi: 10.1007/s12185-009-0261-1
[15]	Alblooshi RM, Deotare U, Michelis FV, et al. My jamais vu in post allogeneic hematopoietic cell transplant: a review on secondary hemophagocytosis in adults[J]. Bone Marrow Transplant, 2020, 55(5): 867-872. doi: 10.1038/s41409-019-0711-1
[16]	Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy-assessment and management of toxicities[J]. Nat Rev Clin Oncol, 2018, 15(1): 47-62. doi: 10.1038/nrclinonc.2017.148
[17]	Shah NN, Highfill SL, Shalabi H, et al. CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor(CAR)T-Cell Potency and Toxicity: Updated Results From a Phase Ⅰ Anti-CD22 CAR T-Cell Trial[J]. J Clin Oncol, 2020, 38(17): 1938-1950. doi: 10.1200/JCO.19.03279
[18]	Fardet L, Galicier L, Lambotte O, et al. Development and Validation of the HScore, a Score for the Diagnosis of Reactive Hemophagocytic Syndrome[J]. Arthritis Rheumatol, 2014, 66(9): 2613-2620. doi: 10.1002/art.38690
[19]	Lehmberg K, Sprekels B, Nichols KE, et al. Malignancy-associated haemophagocytic lymphohistiocytosis in children and adolescents[J]. Br J Haematol, 2015, 170(4): 539-549. doi: 10.1111/bjh.13462
[20]	Trebo MM, Attarbaschi A, Mann G, et al. Histiocytosis following T-acute lymphoblastic leukemia: A BFM study[J]. Leuk Lymphoma, 2009, 46(12): 1735-1741.
[21]	张婉妍, 张园, 董南南, 等. 儿童恶性肿瘤相关性噬血细胞综合征24例临床分析[J]. 中国当代儿科杂志, 2018, 20(4): 295-297. https://www.cnki.com.cn/Article/CJFDTOTAL-DDKZ201804011.htm
[22]	Runge E, Kou CJ, Rendo M, et al. Lenalidomide-Associated Hemophagocytic Lymphohistiocytosis With Plasma Cell Phagocytosis[J]. Cureus, 2021, 13(4): e14409.
[23]	Ambinder AJ, Hambley B, Shanbhag S, et al. Ibrutinib-associated hemophagocytic lymphohistiocytosis: A case series from Johns Hopkins[J]. Am J Hematol, 2019, 94(11): E296-E299.
[24]	Shimazaki C, Inaba T, Nakagawa M. B-cell lymphoma-associated hemophagocytic syndrome[J]. Leuk Lymphoma, 2000, 38(1-2): 121-130. doi: 10.3109/10428190009060325
[25]	Noseda R, Bertoli R, Müller L, et al. Haemophagocytic lymphohistiocytosis in patients treated with immune checkpoint inhibitors: analysis of WHO global database of individual case safety reports[J]. J ImmunoTherapy Cancer, 2019, 7(1): 117. doi: 10.1186/s40425-019-0598-9
[26]	Henter JI, Arico M, Egeler RM, et al. HLH-94: a treatment protocol for hemophagocytic lymphohistiocytosis. HLH study Group of the Histiocyte Society[J]. Med Pediatr Oncol, 1997, 28(5): 342-347. doi: 10.1002/(SICI)1096-911X(199705)28:5<342::AID-MPO3>3.0.CO;2-H
[27]	Ehl S, Astigarraga I, von Bahr Greenwood T, et al. Recommendations for the Use of Etoposide-Based Therapy and Bone Marrow Transplantation for the Treatment of HLH: Consensus Statements by the HLH Steering Committee of the Histiocyte Society[J]. J Allergy Clin Immunol Pract, 2018, 6(5): 1508-1517. doi: 10.1016/j.jaip.2018.05.031
[28]	Lackner H, Seidel MG, Strenger V, et al. Hemophagocytic syndrome in children with acute monoblastic leukemia-another cause of fever of unknown origin[J]. Suppor Care Cancer, 2013, 21(12): 3519-3523. doi: 10.1007/s00520-013-1937-x
[29]	Delavigne K, Berard E, Bertoli S, et al. Hemophagocytic syndrome in patients with acute myeloid leukemia undergoing intensive chemotherapy[J]. Haematologica, 2014, 99(3): 474-480. doi: 10.3324/haematol.2013.097394
[30]	Carter SJ, Tattersall RS, Ramanan AV. Macrophage activation syndrome in adults: recent advances in pathophysiology, diagnosis and treatment[J]. Rheumatology(Oxford), 2019, 58(1): 5-17. doi: 10.1093/rheumatology/key006
[31]	王昭, 王天有. 噬血细胞综合征诊治中国专家共识[J]. 中华医学杂志, 2018, 98(2): 91-95. doi: 10.3760/cma.j.issn.0376-2491.2018.02.004
[32]	Wang Y, Huang W, Hu L, et al. Multicenter study of combination DEP regimen as a salvage therapy for adult refractory hemophagocytic lymphohistiocytosis[J]. Blood, 2015, 126(19): 2186-2192. doi: 10.1182/blood-2015-05-644914
[33]	Marsh RA, Allen CE, McClain KL, et al. Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab[J]. Pediatr Blood Cancer, 2013, 60(1): 101-109. doi: 10.1002/pbc.24188
[34]	Meyer LK, Verbist KC, Albeituni S, et al. JAK/STAT pathway inhibition sensitizes CD8 T cells to dexamethasone-induced apoptosis in hyperinflammation[J]. Blood, 2020, 136(6): 657-668. doi: 10.1182/blood.2020006075
[35]	Maschalidi S, Sepulveda FE, Garrigue A, et al. Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice[J]. Blood, 2016, 128(1): 60-71. doi: 10.1182/blood-2016-02-700013
[36]	Wang J, Zhang R, Wu X, et al. Ruxolitinib-combined doxorubicin-etoposide-methylprednisolone regimen as a salvage therapy for refractory/relapsed haemophagocytic lymphohistiocytosis: a single-arm, multicentre, phase 2 trial[J]. Br J Haematol, 2021, 193(4): 761-768. doi: 10.1111/bjh.17331
[37]	Boonstra PS, Ahmed A, Merrill SA, et al. Ruxolitinib in adult patients with secondary hemophagocytic lymphohistiocytosis[J]. Am J Hematol, 2021, 96(4): E103-E105.